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INTRODUCTION
Alopecia (hair loss) occurs due to many internal factors, such as 
aging or hormonal balance disruption, as well as diverse diseases 
and serious burns or wounds [1,2]. Hair loss is commonly accom-
panied by a region of thinned skin at the bald site [3,4]. Further-
more, these symptoms are due to the functional loss of follicular 
stem cell activity (i.e., forming the hair follicles) [5]. Recently, 
there have been numerous therapeutic trials of various treatments 
for hair loss such as oral medications and hair transplantation 
[6,7]. However, therapeutic drugs, like finasteride and dutasteride, 
provide only temporary improvement, and often with reduced ef-
fectiveness, which results in immediate hair loss [8-10]. Although 
hair transplantation can replace the bald area with healthy hair, 
it is an invasive surgery, and a sufficient number of hairs for re-
placement is not always available in patients with severe hair loss 
[11]. Therefore, alternative therapeutic strategies are essential for 
alopecia.
The hair follicle (HF) cycle includes the phases of growth (ana-
gen), regression (catagen), and rest (telogen) [12]. The activity of 
HFs can be influenced by the internal and external environments 
[13]. The mature HF has a complex structure with multilayered, 
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ABSTRACT Human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) are 
used in tissue repair and regeneration; however, the mechanisms involved are not 
well understood. We investigated the hair growth-promoting effects of hUCB-MSCs 
treatment to determine whether hUCB-MSCs enhance the promotion of hair growth. 
Furthermore, we attempted to identify the factors responsible for hair growth. The 
effects of hUCB-MSCs on hair growth were investigated in vivo, and hUCB-MSCs ad-
vanced anagen onset and hair follicle neogeneration. We found that hUCB-MSCs co-
culture increased the viability and up-regulated hair induction-related proteins of 
human dermal papilla cells (hDPCs) in vitro. A growth factor antibody array revealed 
that secretory factors from hUCB-MSCs are related to hair growth. Insulin-like growth 
factor binding protein-1 (IGFBP-1) and vascular endothelial growth factor (VEGF) 
were increased in co-culture medium. Finally, we found that IGFBP-1, through the co-
localization of an IGF-1 and IGFBP-1, had positive effects on cell viability; VEGF secre-
tion; expression of alkaline phosphatase (ALP), CD133, and b-catenin; and formation 
of hDPCs 3D spheroids. Taken together, these data suggest that hUCB-MSCs promote 
hair growth via a paracrine mechanism.
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concentric epithelial basement cylinders of keratinocytes and a 
distinctive mesenchyme of human dermal papilla cells (hDPCs) 
[14]. hDPCs are the main component of HFs and are widely stud-
ied as the key functional center responsible for controlling the 
hair cycle throughout an animal’s life cycle [15]. The androgen 
activators dihydrotestosterone and dickkopf-1, which can initi-
ate damage-induced apoptosis of hDPCs, are some of the many 
factors involved in androgenic alopecia, where the HF cycle is 
incrementally arrested during the telogen phase and in which 
scalp hair follicles are gradually replaced by smaller follicles [16,17]. 
Thus, hDPCs may play a pivotal role in the pathogenesis of alope-
cia.
Human umbilical cord blood-derived mesenchymal stem cells 
(hUCB-MSCs) have been suggested to promote tissue repair and 
have been used for tissue engineering in numerous studies [18,19]. 
Not only can their multiple lineages replace aged or damaged 
cells, but their secretory factors can enhance tissue repair effi-
ciency [20]. Human mesenchymal stem cells (hMSCs), which are 
capable of self-renewal and differentiation into various mesenchy-
mal tissues, including osteogenic, adipogenic, and chondrogenic 
cell lineages, have been recognized as a promising tool for clinical 
applications [21]. However, the secretion of soluble factors is one 
of the key mechanisms underlying the therapeutic potential of 
hUCB-MSCs recently shown to have therapeutic efficacy in vari-
ous disease models [22,23]. Transplantation of ex vivo-expanded 
hUCB-MSCs improved peripheral neuropathic pain [24] and 
focal cerebral ischemia [25] in rats. Thus, the treatment model 
of hUCB-MSC transplantation has been intensively studied for 
currently-untreated tissue impairments [26]. 
Hair loss from an adult follicle is considered to be a permanent 
state [27,28]. However, there are many therapeutic approaches 
to overcome this irreversible outcome [29]. A previous study has 
demonstrated that HF neo-genesis can be induced in wounds in 
mice in an mIGF-1-dependent manner [30]. On other hand, hair 
follicle stem cell differentiation is disturbed via inhibition of Wnt/
b-catenin [31]. The IGF-1/AKT/GSK3b/b-catenin signaling path-
way is crucial for cell protection and tissue regeneration [32,33]. 
The use of IGF-1/AKT/GSK3b/b-catenin on hDPCs in hair regen-
eration is groundbreaking. In this study, we used hUCB-MSCs 
to determine the effects of both stem cells and their paracrine 
factors on reacquisition of hDPC conduction ability to induce 




C3H/HeJ mice were obtained from Saeron Bio Inc. (Gyeonggi-
do, Korea) and allowed to adapt for one week with free access 
to food and water. The telogen-anagen transition model was in-
duced by depilating the dorsal skin of mice in the telogen phase of 
the hair cycle, as described previously [34]. Starting one day after 
hair removal, minoxidill (3% v/w; Sigma-Aldrich; Merck KGaA, 
Darmstadt, Germany) was topically applied to the minoxidill 
group (MNX) for five days per week. At one day after hair remov-
al, 400 ml of saline or hUCB-MSCs (1×105 cells/mice) were intra-
dermally injected into multiple points (8 sites) in the skin of the 
injection control and hUCB-MSC groups, respectively. The dorsal 
skin was harvested for histological analysis at the end of the ob-
servation period (six weeks). The skin was then fixed in 4% form-
aldehyde and processed by paraffin block embedding using stan-
dard techniques to produce paraffin sections (10 mm thick). The 
general histology was visualized using hematoxylin-eosin (HE) 
staining. Immunohistochemistry was performed on sections 
that had been steamed in 10 mM sodium citrate (pH 6.0, cat. no. 
005000, Fisher Scientific, Inc., Waltham, MA, USA) for 15 min 
prior to incubation with primary antibody. We used antibodies 
directed against b-catenin (1:500, cat. no. 610153, BD Biosciences, 
Franklin Lakes, NJ, USA). Primary antibodies were detected by 
biotinylated secondary antibodies plus streptavidin-peroxidase 
complex (cat. no. SA-5004, VECTOR LABORATORIES, INC., 
Burlingame, CA, USA) and brown FAST DAB staining (cat. no. 
34002, Thermo Fisher Scientific, Inc., Waltham, MA, USA). 
Counterstaining of sections was performed using hematoxylin 
for DAB-stained sections light microscopy (DM750, Leica, Wet-
zlar, Germany). The protocol was approved by the medical ethics 
committee of Chung-Ang University (Seoul, Korea). 
Isolation and culture of hDPCs 
hDPCs were purchased from Cefobio (Seoul, Korea) as primary 
cells and were grown in Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen/Gibco-BRL, Grand Island, NY, USA) sup-
plemented with 5% fetal bovine serum (FBS; Invitrogen/Gibco-
BRL) and 1% penicillin in a humidified environment. hDPCs in 
the third or fourth passage were used.
Patch assay 
The hair-inductive capacity of the hDPCs was assessed in ac-
cordance with the established patch assay [35]. Implantation was 
performed as described previously [36]. Briefly, hUCB-MSCs (U) 
were combined with freshly isolated neonatal mouse epidermal 
(K) and dermal cells (D) and co-transplanted subcutaneously into 
the skin on the backs of nude mice. The normal group, K plus D 
group, K plus U, and K plus D plus U group were injected on the 
same day. Two weeks later, skin samples were dissected from the 
mice and examined to verify hair induction.
Culture of hUCB-MSCs 
This study was approved by the Institutional Review Board of 
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MEDIPOST Co., Ltd. Neonatal hUCB-MSCs were collected from 
umbilical veins. Mononuclear cells were isolated from hUCB by 
centrifugation on a Ficoll-Hypaque gradient (density: 1.077 g/cm3; 
Sigma-Aldrich). The cells were then seeded at 5×105 cells/cm2 in 
culture flasks. After colonies of spindle-shaped cells formed, the 
cells were reseeded for expansion. hUCB-MSCs were cultured in 
αMEM medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA) supplemented with 10% FBS (Gibco) and gentamycin 
(Gibco) in a humidified atmosphere containing 5% CO2 and 3% 
O2 at 37°C. Cells were passaged when they reached 80% conflu-
ency and either used for experiments or redistributed to new cul-
ture plates. In all experiments, hUCB-MSCs used were at passage 
6. 
Human dermal papilla cell isolation and co-culture 
with hUCB-MSCs 
For co-culture experiments, 1×105 hDPCs were seeded into the 
lower chamber of a 6-well transwell plate (Corning, New York, 
NY, USA) containing co-culture medium (DMEM or MEM). 
Immediately after the dermal papilla cells attached, the medium 
was changed, and 2×105 hUCB-MSCs were placed into the upper 
chamber. The plates were incubated at 37°C with 5% CO2 for the 
indicated times before each analysis. 
Cell proliferation assay 
hDPCs were plated at a density of 1×105 cells/well in 6-well 
plates and were continuously cultured for 120 h under each test 
condition. At days 2 and 5 of co-culture with hUCB-MSCs, the 
proliferation was measured using a WST-8 assay (Dojindo; Rock-
ville, MD, USA). WST-8 solution (100 mL) was added to the cells 
in 1 ml incomplete DMEM and incubated for 1 h at 37°C. The ab-
sorbance was then measured at 450 nm using a SpectraMax 190 
microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Alkaline phosphatase (ALP) activity 
hDPCs were seeded at a density of 1×105 cells/mL in 6-well 
plates. At days 2 and 5 of co-culture with hUCB-MSCs, ALP 
activity of the hDPCs was determined enzymologically using an 
ALP assay. After washing with 1X PBS, the cells were incubated 
in 0.1 M NaNO3-Na2CO3 (Sigma-Aldrich) buffer containing 1% 
(v/v) Triton X-100 (Sigma-Aldrich) and 2 mM MgSO4 (Sigma-
Aldrich). Subsequently, 6 mM p-nitrophenyl phosphate (Sigma-
Aldrich) was added as a substrate to each well and incubated for 
30 minutes at 37°C. Finally, 1.5 M NaOH (Sigma-Aldrich) was 
added to stop the enzyme-substrate reaction. Optical density (OD) 
readings were performed at a wavelength of 405 nm using a Spec-
traMax 190 microplate reader (Molecular Devices, Sunnyvale, 
CA, USA).
Human growth factor and cytokine antibody array 
The Raybio® Human Cytokine/Growth Factor Antibody array 
I (RayBiotech, Norcross, GA, USA) was used to assay 23 cytokines 
and 41 growth factors in the supernatants of the cell cultures. The 
array membranes were incubated in blocking buffer for 30 min at 
room temperature (RT), then 1 ml of conditioned medium from 
either the hDPC, hUCB-MSCs, or hDPC plus hUCB-MSCs group 
was added per well, followed by incubation for 1 h at RT. The 
membranes were washed five times in wash buffer at RT, a biotin-
conjugated antibody was added, and the membranes were incu-
bated for 1–2 h at RT. The membranes were washed again, 2 ml 
of HRP-conjugated streptavidin was added, and the membranes 
were incubated for 2 h. Following incubation with detection buf-
fer for 2 min, the luminescence was detected using the LAS 3000 
chemiluminescence imaging system (Fujifilm Inc., Tokyo, Japan) 
and analyzed by densitometry using ImageJ 1.44 software (Na-
tional Institutes of Health, Bethesda, MD, USA).
ELISA
The levels of insulin-like growth factor-1 (cat. no. DG100, R&D 
Systems, Minneapolis, MN, USA), insulin-like growth factor 
binding protein-1 (cat. no. DGB100, R&D Systems), and vascular 
endothelial growth factor (cat. no. DVE00, R&D Systems) in cell 
culture supernatants were quantified using an immunoassay kit. 
After each experiment, the collected medium was added to each 
well and incubated at room temperature for 2 h. The protein ex-
pression level was determined according to the manufacturer’s 
protocol, and absorbance was measured at 450 nm using a Spec-
traMax 190 microplate reader (Molecular Devices).
Western blot analysis 
Western blotting was performed as previously described using 
total protein obtained from hDPCs. Antibodies for phosphorylat-
ed-AKT (1:1000, cat. no. #9271, Cell Signaling Technology, Inc., 
Danvers, MA, USA), AKT (1:1000, cat. no. #4685, Cell Signaling 
Technology, Inc.), phopholyrated-GSK3b (1:1000, cat. no. #9323, 
Cell Signaling Technology, Inc), GSK3b (1:1000, cat. no. #12456, 
Cell Signaling Technology, Inc.), b-catenin (1:1000, cat. no. 
610153, BD Biosciences, Franklin Lakes, NJ, USA), proliferating 
cell nuclear antigen (1:1000, cat. no. #13110, Cell Signaling Tech-
nology, Inc.), b-actin (1:1000, cat. no. sc-4778, Santa Cruz Bio-
technology, Inc., Dallas, TX, USA), ALP (1:100, cat. no. SC-15065, 
Santa Cruz), CD 133 (cat. no. NB120-16518, Novus Biologicals, 
CO, USA) were used as the primary antibodies, and goat anti-
rabbit (cat. no. BA-1000, VECTOR LABORATORIES, INC.) and 
goat anti-mouse (HRP) (cat. no. BA-9200, VECTOR LABORA-
TORIES, INC.) were used as the secondary antibodies (1:10000). 
The blots were analyzed using densitometry with ImageJ 1.44 
software (National Institutes of Health).
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Establishment of hDPC micro-tissues in 3D hanging 
drop cultures
For 3D cell cultures, Perfecta3D Hanging Drop Plates (3D 
Biomatrix Inc., Ann Arbor, MI, USA) were used according to the 
manufacturer’s protocol. To test the effects of IGFBP-1 on hD-
PCs micro-tissue formation, the rhIGFBP-1 (cat. no. 871-B1-025, 
R&D Systems) (+) group was treated with rhIGFBP-1 (100 ng/ml). 
The size distribution of the resulting hDPCs micro tissues was 
analyzed to determine the optimal culture conditions. All hD-
PCs were cultured in serum-free medium (DMEM), which was 
changed every 2 days using a multichannel pipette. The morphol-
ogy and diameter of the hDPC spheroids were recorded using a 
reverse phase-contrast microscope (IX61 FL, Olympus Japan Co.) 
for up to 5 days. 
Immunofluorescence staining 
Immunofluorescence staining in hDPCs was performed as 
previously described [37]. Brief ly, hDPCs were treated with 
rhIGFBP-1 (100 ng/ml) for 2 days. The cells were fixed in 10% 
neutral buffered formalin solution at room temperature for 30 
minutes, permeabilized in 2.5% Tween 20 (cat. no. 9005-64-5, 
Sigma-Aldrich) in PBS for 5 min, then incubated overnight at 
4°C with anti-ALP (1:500, cat. no. SC-15065, Santa Cruz), anti-b-
catenin (1:500, cat. no. BD610154, BD Biosciences), anti-CD 133 
(cat. no. NB120-16518, Novus Biologicals, CO, USA), anti-IGF-1 
(cat. no. SC-9013 Santa Cruz), or anti-IGFBP-1 (cat. no. sc25257, 
Santa Cruz) primary antibody in blocking solution (1:1000). After 
several washes with PBS containing 0.5% Triton X-100 and 0.5% 
BSA, the hDPCs were incubated with anti-rabbit Cy2 (cat. no. 
711-225-152, Jackson ImmunoResearch Inc., PA, USA) or anti–
mouse (cat. no. 715-165-150; Jackson ImmunoResearch Inc.) la-
beled secondary antibodies for 1 h at RT. Following nuclear stain-
ing with DAPI dye (Sigma-Aldrich), the fluorescence signals were 
viewed using a Zeiss confocal laser microscope (LSM 700; Zeiss, 
Heidelberg, Germany).
Statistical analysis 
Significant differences were determined using Student’s t-test, 
with p<0.05 considered to be statistically significant. All data are 
presented as the mean±SEM.
RESULTS
hUCB-MSCs promote hair follicle cycling, 
morphogenesis in vivo
To determine whether hUCB-MSCs promote the anagen hair 
cycle, we injected hUCB-MSCs intra-dermally at multiple sites 
in depilated mouse dorsal skin. Saline injection and daily topical 
treatments of 3% minoxidil were used as controls. We determined 
the hair cycle stage by measuring the status of skin hair regrowth. 
We found that, by 5 weeks of treatment, hUCB-MSCs caused 
diffuse darkening of the dorsal skin, while the control groups 
showed no significant changes (data not shown). At 6 weeks 
of treatment, hair regrowth was complete in the hUCB-MSCs 
group, and the tip of the hair shaft emerged through the epider-
mis. Although the dorsal skin in the minoxidil-treated group had 
incomplete pigmentation and contained hairs in the early stage 
of the hair cycle, the dorsal skin of the normal and saline-injected 
groups retained large areas without anagen induction (Fig. 1A). 
After 6 weeks of treatment, we harvested the dorsal skin for histo-
logical analysis, which indicated that the hUCB-MSCs promoted 
the telogen-anagen transition (Fig. 1B). In particular, the hair fol-
licles that were treated with hUCB-MSCs were transformed from 
the telogen phase to the early- and middle-anagen phases at 6 
weeks (Fig. 1B). Remarkably, the hUCB-MSCs group prematurely 
reentered the anagen phase compared with the minoxidil-treated 
group (Fig. 1B). Furthermore, IHC data revealed that expres-
sion of the b-catenin protein, which is a positive regulator of hair 
growth, was up-regulated in the hUCB-MSCs group compared to 
the other groups (Fig. 1C).
To verify how hUCB-MSCs affect hair follicle morphogenesis, 
we implanted hUCB-MSCs (U) with epithelial stem cells (K) and 
dermal stem cells (D) of neonatal mice into nude mouse. Mixed 
U, K, and D exhibited increased hair follicle induction compared 
to the K plus D group (Figs. 1D and E). Interestingly, the K plus U 
group did not show hair follicle morphogenesis (Figs. 1D and E). 
Collectively, hUCB-MSCs enhanced hair follicle morphogenesis, 
represented as an increase of follicular neogenesis (Figs. 1D and E).
hUCB-MSCs increase cell viability and upregulate hair 
induction-related proteins in hDPCs
Changes in the microbiological environment cause hDPCs to 
lose their conduction ability to induce hair follicle formation in 
humans. To study the effects of hUCB-MSCs on the viability and 
characteristics of hDPCs, we estimated cell viability and ALP 
activity. The effect of hUCB-MSCs on hDPC proliferation and 
ALP activity was revealed using WST-8 and ALP-activity assays. 
hUCB-MSCs co-culture enhanced hDPC proliferation (Fig. 2A) 
and restored ALP activity, both of which are anagen markers of 
the hair cycle in hDPCs in vitro (Fig. 2B) [38].
We further examined AKT/GSK3b/b-catenin pathway regula-
tion and proliferating cell nuclear antigen (PCNA) expression. 
Result revealed that protein expression of phosphorylated Akt 
(Ser473), phosphorylated GSK3b (Ser9), b-catenin, and PCNA 
was pronounced in the hDPCs plus hUCB-MSCs group com-
pared to hDPCs only. These results indicate that b-catenin, AKT, 
and GSK3b, which are proteins contained in the pathway related 
to cell growth and proliferation, were up-regulated in hDPCs 
IGFBP-1 secreted by hUCB-MSCs enhances hair regrowth
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by co-culture with hUCB-MSCs. We found that hUCB-MSCs 
not only promoted expression of hair anagen-induction-related 
proteins, but also upregulated the expression of PCNA in hDPCs 
(Figs. 2C and D). These findings suggest that, in hDPCs, the vi-
ability and ALP activity related to anagen conduction ability can 
be affected and repaired by hUCB-MSCs in vitro, and this effect 
is mainly regulated by AKT/GSK3b/b-catenin signaling.
Growth factor production in hDPC cultures with 
hUCB-MSCs
A screening of growth factor production was performed to 
discover the mechanisms underlying hair anagen induction by 
hUCB-MSCs. Culture media supernatants from hDPCs, hUCB-
MSCs, and hDPCs plus hUCB-MSCs were collected after 5 days 
of culture and analyzed with an antibody array for 42 growth 
factors. Although several factors were detected in the hDPC plus 
hUCB-MSCs group, two growth factors were upregulated in the 
medium of the hDPC plus hUCB-MSCs group compared to the 
hDPC group (Figs. 3A and B). The hDPCs co-cultured in the 
presence of hUCB-MSCs showed a considerably increased levels 
of IGFBP-1 (about >1.25-fold) and VEGF (about >1.25-fold). Nota-
bly, IGFBP-1 was detected in the hUCB-MSCs-only group but less 
in the hDPC-only group. VEGF was also detected in the hUCB-
MSCs groups, but there was no significant difference compared 
to the hDPC-only group. In addition, secretion of IGFBP-2, -6, 
and PDGF-AA were detected both in the hDPCs and hDPCs plus 
hUCB-MSCs group, but there was no statistical significance to 
the increase. In conclusion, it was confirmed that the secretory 
source of IGFBP-1 is hUCB-MSCs.
The actions of IGFs are tightly modulated by a family of pro-
teins called IGF-binding proteins (IGFBPs), of which IGFBP-1 to 
-6 have been characterized [39]. We measured IGF-1 and IGFBP-1 
concentrations in culture media with an ELISA assay. Consistent-
ly, IGFBP-1 was not detected in the hDPCs alone, but the hUCB-
MSCs and hDPC plus hUCB-MSCs group showed increased 
IGFBP-1 level compared to hDPCs alone (Fig. 3C). Additionally, 
VEGF concentration was detected in the hDPC alone group and 
hUCB-MSCs alone group, but it was overwhelmingly upward in 
the hDPC plus hUCB-MSCs compared to each alone group (Fig. 
3D). These results suggest that the IGFBP-1 expression measured 
by the growth factor array is primarily secreted by the hUCB-
MSCs, and this is related to VEGF concentration. In addition, we 
measured IGF-1 concentration in the culture media to determine 
the relationship between IGF-1 and IGFBP-1 expression. The 
protein concentration of IGF-1 was decreased in the hDPC plus 
hUCB-MSCs group compared to the hDPC group (Fig. 3E).
Fig. 1. The effects of hUCB-MSCs on in-
duction of the hair cycle anagen stage 
in mice. The dorsal skin of six-week-
old male C3H/HeJ mice was shaved 
and then injected with saline, treated 
with topical application of 3% minoxidil 
(MNX, 5 times per week), or injected 
with hUCB-MSCs (1×105 cells/head) (A) 
Gross images of hair regrowth in C3H/
HeJ mice treated with either saline, MNX, 
or hUCB-MSCs at six weeks after shaving. 
(B) Histological analysis of dorsal skin 
samples from each group using H&E 
staining. Scale bar, 100 mm (C) Immu-
nohistochemistry, dorsal skin samples 
from each group were stained with anti-
b-catenin, Scale bar, 100 mm. (D) Patch 
assay: at 2 weeks, the nude mice were 
sacrificed, and newly generated hair fol-
licles were counted. Scale bar, 1 mm. (E) 
Bar graph showing the number of each 
hair follicles as mean±SD. *p<0.05 vs. K 
plus D group. **p<0.01, ***p<0.001 vs. 
hDPCs alone.
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IGFBP-1 affects dermal papilla cell viability and 
promotes expression of diverse proteins related to 
hair induction 
IGFBP-1, which was confirmed as the main component secret-
ed by hUCB-MSCs, was studied to explore its independent func-
tion. To investigate the effects of IGFBP-1 on hDPCs, we treated 
hDPCs with recombinant human IGFBP-1 (rhIGFBP-1) protein 
and measured cell viability and VEGF secretion. The results indi-
cated that the viability of hDPCs was significantly increased at 48 
h after rhIGFBP-1 treatment (rhIGFBP-1 concentration: 12.5-200 
ng/ml) (Fig. 4A). Furthermore, VEGF secretion also increased in 
an rhIGFBP-1 concentration-dependent manner in hDPCs (Fig. 
4B). The expression of proteins related to hDPC conduction abil-
ity was confirmed by immunofluorescence in hDPCs. ALP and 
CD133 staining were strong after rhIGFBP-1 treatment (100 ng/
ml) compared to the non-treatment group (rhIGFBP-1 (-)). Ad-
ditionally, b-catenin expression and nuclear translocation were 
increased in the rhIGFBP-1 (+) group (Fig. 4C). Western blot data 
also revealed the upregulated protein expression of ALP, CD133, 
non-phosphorylation-b-catenin (non-p-b-catenin, activation 
form), and b-catenin in the rhIGFBP-1 (+) group (Fig. 4D). To in-
vestigate the characteristics of hDPCs regarding the transforma-
tion to spheres and hair induction structures, the 3D sphere for-
mation velocity of hDPCs was tested by seeding them in hanging-
drop 96-well plates. When the seeding density exceeded 0.25×104 
cells in the hanging-drop 96-well plate, the rapid aggregation of 
hDPC with a loose spheroid structure occurred on day 1, which 
then changed to a compact circular sphere after 5 days of incuba-
tion (Fig. 4E). The diameters of the spheres were quantified using 
phase contrast imaging on day 5. After seeding the hDPCs in 
hanging-drop 96-well plates, hDPCs treated with rhIGFBP-1 (100 
ng/mL) produced spheres with an approximate diameter of 200 
mm, which was larger than the sizes in the rhIGFBP-1 (-) group, 
at day 5. The maximum diameter of the rhIGFBP-1 (-) group was 
approximately half that of the rhIGFBP-1 (+) group (Figs. 4E and 
F). Collectively, these data support the idea that rhIGFBP-1 can 
stimulate cell proliferation; increase secretion of VEGF and en-
hance expression of ALP, CD133, and b-catenin; and promote the 
conduction ability to 3D tissue-like formation.
Fig. 2. The effects of hUCB-MSCs on 
cell viability, ALP activity, and AKT/
GSK3b/b-catenin pathway regula-
tion of hDPCs. hDPCs were co-cultured 
with hUCB-MSCs for 48 h or 120 h in 
two types of culture media (DMEM and 
MEM). (A) The cell viability was estimated 
using a WST-8 assay. (B) ALP activity. (C) 
Representative images of Western blot 
protein assays for p-AKT, AKT, p-GSK3b, 
GSK3b, b-catenin, and proliferating cell 
nuclear antigen (PCNA) in dermal pa-
pilla cells. hDPCs and hUCB-MSCs were 
seeded in 6-well transwell plates. After 
48 h, the cell lysates were harvested for 
Western blot assays. (D) Intensities of the 
immunoreactive bands on the Western 
blots as quantified by densitometric 
analysis. For all graphs, the data is report-
ed as mean±SD. *p<0.01, ***p<0.001 vs. 
hDPCs alone.
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Effects of recombinant protein IGFBP-1 on co-
localization of IGF-1 to dermal papilla cells 
In previous reports, it was demonstrated that IGFBP-1 can act 
either directly or indirectly in biological environments [40] and 
form the complexes with IGF-1 [41]. We hypothesized that in-
creased IGFBP-1 acts as a complex with IGF-1 in hDPCs. There-
fore, we investigated the effects of rhIGFBP-1 treatment on the 
expression of IGF-1 in hDPCs. The results showed that most IGF-
1 was co-localized with IGFBP-1, which was assumed to be the 
main secretory protein of hUCB-MSCs (Fig. 5). Interestingly, the 
protein expression of IGF-1 was slightly elevated in the rhIGFBP-1 
(+) group compared to the rhIGFBP-1 (-) group (Fig. 5). These 
results suggest that secreted IGFBP-1 in hUCB-MSCs co-locate 
with IGF-1 and affects the expression of IGF-1 in hDPCs. 
DISCUSSION
Alopecia is a serious dermatological disease that occurs due to 
diverse reasons [42]. Genetic factors and age have typically been 
considered the main causes of hair loss [43]. Androgenic alopecia 
results in decreased viability of dermal papilla cells and other cells 
comprising hair follicle tissue [16]. Dermal papilla cells play a cen-
tral role in follicular growth and differentiation and direct hair 
follicle cycling by secreting signaling factors to communicate to 
root sheath cells [44]. The hair follicle cycle is affected by andro-
gen and several other factors produced by stressful environments, 
which cause a primary defect in hDPCs signaling, resulting in an 
inability to initiate the hair follicular anagen phase [45,46]. There-
fore, the restoration of hDPCs hair induction ability has been 
considered a potential therapy for hair loss. 
Mesenchymal stem cells (MSCs) exist as a heterogeneous 
population in animals and have great potential for use in tissue 
regeneration [47]. These MSCs are usually distinguished by their 
shape, small size, and high nuclear fluctuation, which determine 
their “stemness” and therapeutic capacity [48]. Attempts to regen-
erate tissue using biological factors secreted by UCB-MSCs have 
recently been reported [49,50]. In a previous study, implantation 
of BM-MSCs in normal and diabetic mice enhanced wound heal-
ing associated with increased angiogenesis [51]. In another study, 
mesenchymal stem cell transplantation has beneficial results due 
to its anti-inflammation potential in cardiac infarction damage 
[52]. In addition, intravenous injection of hUCB-MSCs has a role 
in the prevention of obesity as a mediator in macrophage polar-
ization [53]. The effects of MSCs on tissue regeneration and anti-
inflammatory effects have been verified, and the functions and 
main factors causing the therapeutic effects of MSCs have been 
widely explored [54]. In this study, hUCB-MSCs triggered hair 
anagen induction from the telogen phase in vivo. Furthermore, 
Fig. 3. Growth factor secretion profiles 
of hDPCs alone, hUCB-MSCs alone, 
and hDPCs plus hUCB-MSCs. (A) Rep-
resentative images of the growth factor 
antibody array analysis in culture media 
obtained at 48 h of growth in each 
group. (B) Quantification of the cytokine 
array analysis of the culture media as 
the fold increase compared with hDPCs 
alone. The protein concentration in 
each culture media measured individual 
protein with ELISA. (C) IGFBP-1, (D) VEGF, 
and (E) IGF-1. Abbreviations are as fol-
lows: IGFBP-1, -2, and -6, insulin-like 
growth factor binding protein-1, -2, and 
-6; PDGF-AA, platelet-derived growth 
Factor-AA; VEGF, vascular endothelial 
growth factor; IGF-1, insulin-like growth 
factor-1. The data are reported as mean± 
SD. *p<0.05, **p<0.01, vs. hDPCs alone.
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hUCB-MSCs emphasized hair follicle morphogenesis, but in case 
of ablation of the neonatal dermal cell, hUCB-MSCs and epitheli-
al cells did not undergo hair follicle generation. We assumed that 
hUCB-MSCs are not the main component of the newly generated 
hair follicle and may play a role in assisting dermal cells to con-
duct tissue generation. These findings indicate that hUCB-MSCs 
facilitate hair follicle regeneration and hair growth via a paracrine 
mechanism. In a previous report, MSC-conditioned medium 
that was modified to overexpress Wnt1a restored the hair cycle 
in vivo [34]. In another study, BM-MSCs increased angiogenesis 
in a diabetic mice wound model [51]. However, BM-MSCs were 
located adjacent to the vasculature rather than in the vascular 
walls [51]. This indicates that a paracrine effect of MSCs plays a 
major role in angiogenesis and wound healing. In this study, we 
demonstrated that hDPCs co-cultured with hUCB-MSCs in a de-
tached environment had increased cell viability and ALP activity 
and up-regulated the AKT/GSK3b/b-catenin pathway, indicating 
that paracrine factors have a major role in recruitments of hDPC 
conduction ability in vitro. 
Insulin-like growth factor 1 (IGF-1) is an important growth 
factor in many biological environments [55,56]. In a previous 
report, it was found to have substantial structural homology with 
insulin and influence food intake and glucose metabolism in 
a similar manner to insulin [57]. Recently, IGF-1 has been sug-
gested to play a crucial role in regulating cellular differentiation 
and tissue generation during the development of hair follicles [58]. 
Fig. 4. The effects of recombinant 
IGFBP-1 on hDPC viability, VEGF se-
cretion, expression of proteins related 
to hair anagen induction, and forma-
tion of 3D tissue-like structures of 
hDPCs. (A) Cell viability. Control hDPCs 
(Cont.) and IGFBP-1 (12.5-200 ng/ml)-
treated hDPCs were cultured for 48 h, 
and the cell viability was measured using 
an WST-8 assay. (B) VEGF concentration 
in the culture media. Cont. and IGFBP-1 
(12.5-200 ng/ml)-treated hDPCs were 
cultured for 48 h. The culture media 
was harvested, and VEGF concentration 
was measured using an ELISA assay. (C) 
Immunofluorescent staining of protein 
ALP, CD133, and b-catenin in hDPCs. 
rhIGFBP-1 (100 ng/ml) was administered 
to hDPCs (1×105) for 48 h. The cells were 
then stained to visualize the expres-
sion of anti-ALP, -CD133, and -b-catenin 
(Green). Scale bar 5 µm. (D) Representa-
tive images of Western blot. Cell lysates 
of hDPCs without or with rhIGFBP-1 
(100 ng/mL) were immunoprobed with 
anti-ALP, -CD133, non-p-b-catenin, and 
b-catenin. Effect of rhIGFBP-1 (100 ng/
mL) on the formation of hDPC spheroids 
after seeding for 5 days. (E) Representa-
tive images of passage 8-hDPCs from 
each treatment group (n=4) aggregated 
into microtissues in a regular manner 
(0.25×104 cells/well, scale bar 200 mm). 
(F) The bar graph shows the maximum 
tissue diameter produced in each group 
at Day 5. For all graphs, the data is shown 
as mean±SD. **p<0.01, ***p<0.001, vs. 
Cont. #p<0.01 vs. IGFBP (-).
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To exert its physiological effects, IGF-1 activates cells by binding 
to specific cell-surface receptors [58]. In the circulatory system, 
this biological factor mediates the endocrine action of growth 
hormones on cellular growth and forms complexes with specific 
binding proteins (BPs) [41]. 
There are six insulin-like growth factor binding proteins 
(IGFBP-1~-6), which bind to IGF-1 and -2 with very high affinity 
[41]. Because their affinity to IGFBP is 2- to 50-fold greater than 
that of IGF-IR, these IGFBPs can modulate the distribution of 
IGF among the proteins in interstitial fluids [41]. In this study, 
we hypothesized that IGFBP-1 was be a major factor affecting 
dermal papilla cells. We assumed that, since IGF-1 protein is the 
autocrine factor of hDPCs bound to hDPCs with the assistance of 
IGFBP-1, its concentration in culture media was decreased com-
pared to that of the non-assisted group (hDPCs alone). 
Cells within hDPCs and dermal sheath (DS) are specially iden-
tified as mesenchymal cells and express distinct enzymes and 
molecules. Although the functions of most of these protein mark-
ers are not fully understood, they have been used to identify hD-
PCs and DS. The expression of some markers, like ALP and ver-
sican, correlates with hair inductive properties [59]. hDPCs easily 
lose their characteristics and conductivity in vitro in the absence 
of additional factors, such as WNT- or BMP-signaling [60]. In a 
previous report, beta-catenin was upregulated in hDPCs, result-
ing in increased expression of the mesenchymal stem cell marker 
CD133 [61]. Furthermore, this anagen-conductive protein is also 
increased during the formation of hDPCs 3D tissue-like aggre-
gates in vitro and in vivo [62]. In this study, rhIGFBP-1 not only 
increased hDPCs viability and VEGF secretion, but also upregu-
lated the protein expression of ALP, beta-catenin, and CD133. 
In addition, rhIGFBP-1 enhanced the formation velocity of 3D 
tissue-like aggregates of hDPCs in vitro. These results indicate 
that IGFBP-1 has a positive role in maintaining cell longevity and 
regulating the conduction ability of hair anagen momentum. 
IGFBPs can affect cells directly or indirectly and modulate the 
function of IGF-1 in an endocrine, paracrine, or autocrine man-
ner through IGF-1/IGFBP complexes [41]. In a previous report, 
when IGFBP-1 and IGF-1 were added to porcine aortic smooth 
muscle or human fibroblast cultures, the IGF-1/IGFBP-1 com-
plex enhanced DNA synthesis compared to treatment with IGF-
1 alone [41]. Additionally, IGFBP-1 allowed IGF-1 to remain in 
equilibrium with its high-affinity receptors for a prolonged in-
terval [40,41]. In our results, rhIGFBP-1 formed a co-localization 
with IGF-1. Notably, this result suggests that the IGF-1/IGFBP-1 
co-localization facilitates the interaction of IGF-1 with its recep-
tor in hDPCs during the progression of the cell cycle. 
In this study, we demonstrated that hUCB-MSCs can acceler-
ate the initiation of the hair follicle telogen-anagen transition, 
increase the number of hairs in vivo, and enhance expression 
of proteins related to hair induction in vitro. Notably, IGFBP-1 
(assumed as the main secretory factor of hUCB-MSCs) restores 
and promotes the hair-induction ability of hDPCs via an IGF-1/
IGFBP-1 co-localization. Taken together, our findings indicate 
that hUCB-MSCs and their secretory protein IGFBP-1 can restore 
the ability of hDPCs to induce hair follicle regeneration, poten-
tially providing alternative therapeutic methods for alopecia. In 
general, the immunosuppressive effect of the mesenchymal stem 
cell treatment is well known, as mentioned above. The occurrence 
of hair loss is also complex, and the immune response is one of its 
major causes. We would need to further investigate the effects of 
stem cell therapies on hair loss in a variety of biological environ-
ments.
Fig. 5. The effects of recombinant IGFBP-1 on the expression of IGF-1 on hDPCs via the co-localization of an IGF-1 and IGFBP-1. hDPCs (1×105 
cells) were treated with rhIGFBP-1 (100 ng/mL) for 48 h and then stained with anti-IGF-1 (green), anti-IGFBP-1 (red), and DAPI (nucleus, blue). Scale bar 
20 mm.
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